Ocugen Inc (OCGN) Stock Price, Quote & News

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 328 4701

Website: www.ocugen.com

Address:

11 Great Valley Parkway, Malvern, United States

Bio_Apple Jul. 15 at 7:18 AM

$OCGN Attention everyone—take a look at the latest data: 1. 33.28% Short Float 🫨 🤓 That is extremely high. Roughly one in three freely tradable shares is sold short. Figures like this are seen in only a few US stocks. 2. 24.24 Days to Cover 🤪 In my view, this is the most striking figure 🚀

0 · Reply

Djtrush Jul. 15 at 6:17 AM

$OCGN Soon. Holding on.

0 · Reply

SmoldyShatStone Jul. 15 at 4:38 AM

$OCGN lmao straight to Uranus BIGbags008 😂😂😂

0 · Reply

TouchHoole Jul. 15 at 4:18 AM

$OCGN hope we get to $25 I have 33 shares at 16.70 🤷

0 · Reply

Jag2441 Jul. 15 at 4:12 AM

$OCGN From 4pm EST nothing but Algorithmic trading.

0 · Reply

SIRWINSALOT Jul. 15 at 3:57 AM

$OCGN $25 MINIMUM

1 · Reply

CasaDePapel Jul. 15 at 3:41 AM

$OCGN Shanky killed the momentum no one trusts this Scammer anymore! Pumps and dumps from fake bulls this is all this ticker will get! Manipulation! I’m glad I sold most of my position!

0 · Reply

BIGbash008 Jul. 15 at 3:05 AM

$OCGN ....all set for Pluto

1 · Reply

realwatcher Jul. 15 at 1:39 AM

$OCGN

0 · Reply

realwatcher Jul. 15 at 1:38 AM

$OCGN

1 · Reply

Ocugen announces $4M OCU400 license agreement with Roots Pharmaceutical

Jul 13, 2026, 7:02 AM EDT - 1 day ago

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Jul 10, 2026, 10:00 AM EDT - 4 days ago

Ocugen Transcript: Piper Sandler Virtual Ophthalmology Day

Jul 1, 2026, 7:00 AM EDT - 13 days ago

Ocugen to Participate in Upcoming July Industry Conferences

Jun 11, 2026, 8:00 AM EDT - 4 weeks ago

Ocugen Transcript: AGM 2026

Jun 4, 2026, 2:30 PM EDT - 5 weeks ago

Ocugen Transcript: Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Jun 2, 2026, 7:03 AM EDT - 6 weeks ago

Ocugen to Participate in Upcoming June Investor and Industry Conferences

2026-05-27T11:37:17.000Z - 6 weeks ago

Ocugen price target lowered to $11 from $12 at Canaccord

May 26, 2026, 10:30 AM EDT - 7 weeks ago

Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 14, 2026, 4:30 PM EDT - 2 months ago

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

May 13, 2026, 7:02 AM EDT - 2 months ago

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

2026-05-05T13:15:52.000Z - 2 months ago

Ocugen reports Q1 EPS (6c), consensus (5c)

May 5, 2026, 8:32 AM EDT - 2 months ago

Ocugen Provides Business Update with First Quarter 2026 Financial Results

May 5, 2026, 8:30 AM EDT - 2 months ago

Ocugen Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 2 months ago

Ocugen Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 2 months ago

Ocugen Quarterly report: Q1 2026

May 5, 2026, 8:12 AM EDT - 2 months ago

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

2026-05-04T20:16:05.000Z - 2 months ago

Ocugen announces private offering of $115M of convertible senior notes

May 4, 2026, 4:01 PM EDT - 2 months ago

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Apr 29, 2026, 7:02 AM EDT - 2 months ago

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Ocugen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Ocugen Proxy statement: Proxy filing

Apr 23, 2026, 7:02 AM EDT - 2 months ago

Ocugen to Present at April 2026 Investor and Industry Conferences

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Ocugen Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Ocugen Proxy statement: Proxy filing

2026-04-01T11:56:15.000Z - 3 months ago

Ocugen completes dosing in GARDian3 trial

Apr 1, 2026, 7:02 AM EDT - 3 months ago

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

2026-03-25T13:20:15.000Z - 3 months ago

Ocugen price target raised to $12 from $8 at Noble Capital

2026-03-25T10:11:21.000Z - 3 months ago

Ocugen price target raised to $10 from $7 at H.C. Wainwright

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Ocugen Transcript: Study update

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Ocugen Press release: Study update

2026-03-24T11:55:27.000Z - 4 months ago

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

Mar 24, 2026, 7:45 AM EDT - 4 months ago

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Mar 23, 2026, 7:02 AM EDT - 4 months ago

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

2026-03-17T11:30:27.000Z - 4 months ago

Ocugen initiated with a Buy at Canaccord

2026-03-11T10:40:53.000Z - 4 months ago

Ocugen initiated with an Outperform at Oppenheimer

2026-03-11T10:10:53.000Z - 4 months ago

Ocugen price target raised to $22 from $15 at Lucid Capital

Mar 4, 2026, 8:30 AM EST - 4 months ago

Ocugen Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 4 months ago

Ocugen Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 4 months ago

Ocugen Earnings release: Q4 2025

2026-03-04T13:28:15.000Z - 4 months ago

Ocugen reports Q4 EPS (6c), consensus (6c)

Mar 4, 2026, 8:15 AM EST - 4 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 7:02 AM EST - 4 months ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Feb 9, 2026, 7:02 AM EST - 5 months ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Jan 23, 2026, 8:00 AM EST - 6 months ago

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Jan 21, 2026, 8:32 AM EST - 6 months ago

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Jan 15, 2026, 8:30 AM EST - 6 months ago

Ocugen Transcript: Study result

Jan 15, 2026, 8:30 AM EST - 6 months ago

Ocugen Press release: Study result

Jan 15, 2026, 8:15 AM EST - 6 months ago

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jan 13, 2026, 7:00 AM EST - 6 months ago

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Jan 12, 2026, 6:30 AM EST - 6 months ago

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Jan 9, 2026, 7:02 AM EST - 6 months ago

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Dec 10, 2025, 9:20 AM EST - 7 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Nov 20, 2025, 7:02 AM EST - 8 months ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 5, 2025, 8:30 AM EST - 8 months ago

Ocugen Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 8 months ago

Ocugen Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 8 months ago

Ocugen Earnings release: Q3 2025

Nov 5, 2025, 6:30 AM EST - 8 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 9 months ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Sep 25, 2025, 9:30 AM EDT - 10 months ago

Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025

Sep 15, 2025, 6:03 AM EDT - 10 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 2, 2025, 7:02 AM EDT - 11 months ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Aug 13, 2025, 6:27 AM EDT - 11 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 12, 2025, 3:45 PM EDT - 1 year ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 1 year ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings Call Transcript: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Quarterly report: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings release: Q2 2025

Aug 1, 2025, 8:25 AM EDT - 1 year ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Jul 21, 2025, 7:30 AM EDT - 1 year ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 18, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 17, 2025, 6:30 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jun 23, 2025, 7:30 AM EDT - 1 year ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 16, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 11, 2025, 7:30 AM EDT - 1 year ago

Ocugen To Present at BIO International Convention 2025

Jun 5, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

May 27, 2025, 7:02 AM EDT - 1 year ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Quarterly report: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings release: Q1 2025

May 9, 2025, 8:01 AM EDT - 1 year ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Apr 8, 2025, 8:02 AM EDT - 1 year ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Mar 18, 2025, 8:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Annual report: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings release: Q4 2024

Mar 5, 2025, 7:02 AM EST - 1 year ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 8:46 AM EST - 1 year ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 21, 2025, 8:00 AM EST - 1 year ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 7:42 AM EST - 1 year ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 3, 2025, 6:30 AM EST - 1 year ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Bio_Apple Jul. 15 at 7:18 AM

0 · Reply

Djtrush Jul. 15 at 6:17 AM

$OCGN Soon. Holding on.

0 · Reply

SmoldyShatStone Jul. 15 at 4:38 AM

$OCGN lmao straight to Uranus BIGbags008 😂😂😂

0 · Reply

TouchHoole Jul. 15 at 4:18 AM

$OCGN hope we get to $25 I have 33 shares at 16.70 🤷

0 · Reply

Jag2441 Jul. 15 at 4:12 AM

$OCGN From 4pm EST nothing but Algorithmic trading.

0 · Reply

SIRWINSALOT Jul. 15 at 3:57 AM

$OCGN $25 MINIMUM

1 · Reply

CasaDePapel Jul. 15 at 3:41 AM

$OCGN Shanky killed the momentum no one trusts this Scammer anymore! Pumps and dumps from fake bulls this is all this ticker will get! Manipulation! I’m glad I sold most of my position!

0 · Reply

BIGbash008 Jul. 15 at 3:05 AM

$OCGN ....all set for Pluto

1 · Reply

realwatcher Jul. 15 at 1:39 AM

$OCGN

0 · Reply

realwatcher Jul. 15 at 1:38 AM

$OCGN

1 · Reply

Dfwmb Jul. 15 at 12:46 AM

$OCGN it is all about the science!

0 · Reply

icervantes Jul. 15 at 12:19 AM

$OCGN adding 100 at a time, added another hundred today.😁

1 · Reply

icervantes Jul. 15 at 12:16 AM

$OCGN

0 · Reply

Perso Jul. 15 at 12:14 AM

$OCGN I added 2000 shares today, you only live once!!!!

1 · Reply

2RICH4U Jul. 14 at 11:53 PM

$OCGN this should be at 2.50 min

0 · Reply

JayCalidelphia Jul. 14 at 11:50 PM

$OCGN Fuck yo PUTS. 📈

0 · Reply

brainless Jul. 14 at 10:52 PM

$OCGN

0 · Reply

joetho Jul. 14 at 9:55 PM

$OCGN holding

1 · Reply

realditzy Jul. 14 at 8:55 PM

$OCGN

0 · Reply

SteepDescent_ Jul. 14 at 8:41 PM

$OCGN There is also a communication inconsistency worth noting. The latest MENA release says the Phase 3 readout is expected in Q1 2027 with the BLA submission to follow, while the latest SEC filing says the rolling submission should begin in Q3 2026 and be completed in Q2 2027. That is only consistent if submission in the press release means completion, but Ocugen should communicate such a central milestone much more precisely.

2 · Reply

WayLoSellHi Jul. 14 at 8:15 PM

$OCGN Green day on micro volume still looks to be holding this level of support aka "Wait & See mode" With these spammers tagging OCGN as part of their "Next to be sent" post maybe just maybe the parabolic algo will pick up our ticker & send it by mistake 😅 With this crazy mkt anything & everything is possible 🤖

0 · Reply

2026ocu Jul. 14 at 8:14 PM

$OCGN i‘m waiting for the interim results of OCU410ST

0 · Reply

Market Cap	477.32M
Revenue (ttm)	4.41M
Net Income (ttm)	-67.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,538.55%
Debt to Equity Ratio	5.03

Volume	4,963,500
Avg Vol	8,305,046
Day's Range	N/A - N/A
Shares Out	338.52M
Stochastic %K	23%
Beta	2.18
Analysts	Strong Sell
Price Target	$10.22